Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.62 |
| ▸ | STS | P08842 | 7/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 6/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP7 | P09237 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161814 | 0.87 | GPR119 (0.48) | GPR119STSNAMPTMMP13MMP1 | |
| SCHEMBL4519083 | 0.86 | GPR119 (0.76) | GPR119NAMPT | |
| SCHEMBL4242101 | 0.83 | GPR119 (0.66) | GPR119STSMMP13 | |
| SCHEMBL3486329 | 0.82 | GPR119 (0.77) | GPR119STS | |
| SCHEMBL6917548 | 0.82 | NAMPT (0.67) | GPR119STSNAMPT | |
| SCHEMBL9829743 | 0.82 | QDPR (0.54) | GPR119 | |
| SCHEMBL4247141 | 0.81 | GPR119 (0.58) | GPR119STSMMP13MMP1MMP3 | |
| SCHEMBL3343409 | 0.81 | GPR119 (0.69) | GPR119STSNAMPT | |
| Dimethylamine SCHEMBL6608623 | 0.81 | NAMPT (0.65) | GPR119STSNAMPT | |
| SCHEMBL18379198 | 0.81 | GPR119 (0.62) | GPR119STSNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | GPR119 2/4885STS 604/4885NAMPT 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.